Skip to main content
NEWLAND PHARMACEUTICAL CO., LTD logo

NEWLAND PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 301277 ISIN · CNE1000065K2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2025-01-07 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 301277

About NEWLAND PHARMACEUTICAL CO., LTD

https://www.newlandpharma.com

Newland Pharmaceutical Co., Ltd. is a specialized enterprise engaged in the research, development, manufacturing, and global distribution of active pharmaceutical ingredients (APIs) and high-quality chemical intermediates. The company focuses on a broad spectrum of therapeutic categories, including cardiovascular, anti-infective, and metabolic health solutions. Operating with a commitment to rigorous quality control, its production facilities are designed to meet international Good Manufacturing Practice (GMP) standards. Newland Pharmaceutical prioritizes technological innovation and chemical synthesis optimization to deliver reliable pharmaceutical components. Its core operations involve the large-scale production of complex molecules, supporting the supply chains of healthcare providers and pharmaceutical formulators worldwide through a focus on technical excellence and regulatory compliance.

Recent filings

Filing Released Lang Actions
关于获得化学原料药上市申请批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company about receiving an approval notice from the National Medical Products Administration for a chemical raw material drug listing application. It details the approval, drug information, and impact on the company. The document is short (971 characters) and serves as a formal announcement of regulatory approval rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or audit information. It is not a report itself but an announcement of a regulatory approval event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-01-07 Chinese
华泰联合证券有限责任公司关于新天地药业股份有限公司2024年度持续督导培训情况的报告
Audit Report / Information Classification · 90% confidence The document is a report from Huatai United Securities Co., Ltd. regarding the 2024 continuous supervision training conducted for the main directors, supervisors, senior management, and middle-level management of Xintiandi Pharmaceutical Co., Ltd. It references regulatory guidelines from the Shenzhen Stock Exchange and the China Securities Regulatory Commission. The content focuses on the training activities, participants, and outcomes related to compliance and understanding of merger and acquisition regulations. The document is relatively short (1120 characters) and is a specific report on a training activity rather than a financial report, regulatory filing, or announcement of voting results. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a specialized report on continuous supervision training, which aligns best with Audit Report / Information (AR) as it relates to regulatory compliance and internal control training activities. Therefore, the most appropriate classification is AR with high confidence. FY 2024
2024-12-31 Chinese
华泰联合证券有限责任公司关于新天地药业股份有限公司2024年度现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "现场检查报告" (On-site Inspection Report) for the year 2024 by 华泰联合证券有限责任公司, the sponsor for 新天地药业股份有限公司's IPO and listing on the ChiNext board. It references regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange guidelines related to sponsor duties and compliance. The content details the sponsor's on-site inspection covering governance, internal control, information disclosure, protection of company interests, use of raised funds, performance, and fulfillment of commitments. It is a detailed compliance and inspection report by the sponsor, not a full annual report or audit report. It is not a simple announcement or certification but a substantive report on regulatory inspection findings. This type of document fits best under Audit Report / Information (AR) as it relates to regulatory compliance and sponsor audit findings, distinct from the full Annual Report (10-K) or other categories. FY 2024
2024-12-31 Chinese
关于收到政府补助的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (410 characters) about the company receiving a government subsidy. It includes a statement from the board ensuring the accuracy of the announcement and some accounting treatment notes. There is no detailed financial data, no full report, no earnings summary, no management discussion, and no regulatory certification. The document is an announcement of a specific event (receipt of government subsidy) rather than a full financial report or detailed filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Audit Report. It is not a report publication announcement since it does not mention any report being published or attached. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2024-12-26 Chinese
关于使用部分闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 新天地药业股份有限公司 regarding the use of temporarily idle raised funds for cash management. It details board and supervisory committee meetings approving the use of up to 370 million RMB of idle raised funds for cash management products with a maximum term of 12 months. The document references regulatory approvals, fundraising details, and compliance with securities regulations. It is not a full financial report but a specific announcement about the use of raised funds and related board resolutions. The document length is about 5279 characters, which is substantial but the content is focused on a specific financing/capital management update rather than a full annual or interim report. Therefore, the best fitting category is Capital/Financing Update (CAP).
2024-12-02 Chinese
关于公司药品生产许可证变更的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the change of its drug production license issued by the Henan Provincial Drug Administration. It details the updated license information, production scope, and the impact on the company. The document is short (1019 characters) and serves as a formal notification of a regulatory change rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed governance information. It is not a report publication announcement since it contains substantive content about the license change. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-12-02 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.